Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4406

This is a description of a medication containing Fluticasone Propionate and Salmeterol Inhalation Diskus in powder form. The medication comes in blister packaging with 60 blisters per quantity. It is essential to store the inhalation diskus in a dry place away from direct heat or sunlight. The medication is for oral inhalation only, and the usual dosage information can be found in the insert provided. This product was repackaged by RemedyRepack Inc., located in Indiana, PA. The manufacturer is Hikima based in Berkeley Heights, NJ. Remember to keep the medication out of the reach of children and store it within the temperature range of 20-25°C (68-77°F), with excursions allowed up to 15-30°C (59-86°F) as per USP guidelines.*

This is a comparison of the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder at 250 mcg/50 mcg twice daily, Salmeterol at 50 mcg twice daily, and a Placebo on baseline FEV (Forced Expiratory Volume) over the course of the study measured over 24 weeks. The graph shows the lung function improvement for each treatment group, indicating the potential benefits of using the Fluticasone Propionate and Salmeterol Inhalation Powder.*

The text provides a comparison of the effectiveness of Fluticasone Propionate and Salmeterol Inhalation Powder in different doses with Fluticasone Propionate alone, Salmeterol alone, and a Placebo. It shows the results over several weeks. The combination of Fluticasone Propionate and Salmeterol Inhalation Powder (100 mcg/50 mcg) twice daily had higher efficacy than the individual components or the Placebo, as depicted by the percentage values provided in the table.*

This data illustrates the percentage change in FEV4 on the first treatment day for different medication groups including Fluticasone Propionate and Salmeterol Inhalation Powder, Salmeterol, Fluticasone Propionate, and Placebo. The chart shows the comparison of these treatments over hours, indicating the impact on FEV4 levels.*

This is a description of a study comparing the impact of different treatment plans on lung function over a period of 12 weeks. The study involves the use of Fluticasone Propionate and Salmeterol Inhalation Powder at different dose levels and frequencies, as well as a placebo. The data includes the number of participants in each treatment group and their percentage change in forced expiratory volume relative to the baseline measurements taken on Day 1. The results are reported for Week 12 and the Last Treatment Day.*

This product appears to be a counter device with an outer case and a thumb grip for ease of use. Additionally, it comes with a mouthpiece that may be used for certain functionalities.*